# Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

> **NCT00022022** · PHASE3 · UNKNOWN · sponsor: **Istituto Nazionale per lo Studio e la Cura dei Tumori** · enrollment: 200 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00022022
- **Lead sponsor:** Istituto Nazionale per lo Studio e la Cura dei Tumori
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022022, "Docetaxel in Treating Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00022022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*